Shree Ganesh Remedies Ltd Reports Mixed Quarterly Results Amid Shifting Financial Trends

Quarterly Performance Highlights

In the quarter ended March 2026, Shree Ganesh Remedies Ltd achieved its highest-ever net sales of ₹33.20 crores, marking a significant milestone for the company. This top-line growth was accompanied by a peak PBDIT (Profit Before Depreciation, Interest and Taxes) of ₹11.38 crores, underscoring improved operational efficiency. Furthermore, the company reported its highest PBT less other income at ₹7.70 crores, reflecting solid core profitability before non-operating items.

Despite these encouraging figures, the company’s overall financial trend has shifted negatively, with the financial trend score declining to -5 from -22 over the past three months. This suggests that while quarterly results show pockets of strength, underlying financial health is under pressure.

Profitability and Margin Analysis

One area of concern is the company’s net profit after tax (PAT) over the latest six months, which has contracted by 22.06% to ₹9.36 crores. This decline in bottom-line profitability contrasts with the growth in sales and operating profits, indicating margin pressures or increased costs impacting net earnings. The return on capital employed (ROCE) for the half-year period also hit a low of 14.23%, signalling reduced efficiency in generating returns from invested capital.

Such margin contraction and lower capital returns are critical for investors to monitor, as they may reflect rising expenses, pricing pressures, or operational inefficiencies that could weigh on future earnings growth.

Working Capital and Liquidity Metrics

The company’s debtors turnover ratio for the half-year period stands at 3.36 times, the lowest in recent history. This metric indicates slower collection of receivables, which could strain working capital and cash flow management. Efficient receivables management is vital in the pharmaceutical sector, where timely cash realisation supports ongoing research, production, and distribution activities.

Stock Price Movement and Market Capitalisation

Shree Ganesh Remedies Ltd’s stock price has demonstrated notable volatility and strength in recent sessions. The current price stands at ₹576.00, up 15.57% on the day, with intraday highs reaching ₹598.00. This marks a substantial recovery from the 52-week low of ₹381.10, though still below the 52-week high of ₹794.00. The company remains classified as a micro-cap, reflecting its relatively small market capitalisation within the broader pharmaceuticals sector.

Comparative Returns Versus Sensex

When benchmarked against the Sensex, Shree Ganesh Remedies Ltd has delivered mixed returns across different time horizons. Year-to-date (YTD), the stock has surged 24.35%, outperforming the Sensex’s decline of 11.68%. Over the past month, the stock gained 16%, while the Sensex fell 3.65%. However, over the trailing one-year period, the stock underperformed with a negative return of 20.44% compared to the Sensex’s -8.81%. Longer-term performance remains robust, with three- and five-year returns at 95.69% and 132.07% respectively, significantly outpacing the Sensex’s 20.72% and 54.44% gains.

This disparity highlights the stock’s cyclical nature and sensitivity to sector-specific factors, as well as the importance of a long-term investment horizon for shareholders.

Financial Trend Shift and Rating Update

MarketsMOJO’s proprietary Mojo Score for Shree Ganesh Remedies Ltd currently stands at 37.0, with a Mojo Grade of Sell. This represents an upgrade from the previous Strong Sell rating assigned on 12 January 2026, reflecting some improvement in recent financial metrics despite ongoing challenges. The shift from a flat to a negative financial trend underscores the need for cautious monitoring of the company’s operational and financial developments in the coming quarters.

Outlook and Investor Considerations

Investors analysing Shree Ganesh Remedies Ltd should weigh the company’s record quarterly sales and operating profits against the contraction in net profit and declining efficiency ratios. The negative financial trend score and modest Mojo Grade Sell rating suggest that while the company is stabilising from a prior weak phase, risks remain in terms of margin sustainability and working capital management.

Given the stock’s strong long-term returns relative to the Sensex, patient investors with a tolerance for micro-cap volatility may find value in the company’s growth prospects. However, those seeking more stable earnings and stronger financial health might consider alternative opportunities within the Pharmaceuticals & Biotechnology sector or broader market.

Monitoring upcoming quarterly results and management commentary will be crucial to assess whether Shree Ganesh Remedies Ltd can reverse the negative trend and improve profitability metrics in the near term.

Summary

Shree Ganesh Remedies Ltd’s March 2026 quarter results present a mixed picture: record sales and operating profits contrast with declining net profit and efficiency ratios, signalling a shift to a negative financial trend. The stock’s recent price strength and long-term outperformance versus the Sensex offer some optimism, but investors should remain cautious given the company’s micro-cap status and ongoing margin pressures.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today